Medtronic Just Posted Its Best Quarter in 2.5 Years - 24/7 Wall St.[S&P 5006,801.40 -0.57%][Dow Jones49,305.60 -0.48%][Nasdaq 10024,498.60 -0.73%][Russell 20002,624.86 -0.54%][FTSE 10010,519.70 +0.48%][Nikkei 22556,668.00 -0.19%][Stock Market Live February 17, 2026: S&P 500 (ETF) Fighting to Go Green Again][Investing]# Medtronic Just Posted Its Best Quarter in 2.5 Years### Quick ReadMedtronic (MDT) delivered its strongest revenue growth in 10 quarters and beat Wall Street on revenue and earnings.Medtronic's ...

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is expected to report a quarterly loss of -$0.05 per share, marking an 88.6% increase in loss compared to the same period last year [1] - Analysts forecast revenues of $276 million, reflecting a year-over-year increase of 9.3% [1] - The consensus EPS estimate has been adjusted downward by 0.8% over the past 30 days, indicating a reassessment by covering analysts [1] Revenue Estimates - Analysts project 'Revenue- Supplies and Other' to reach $141.55 million, indicating a year-over-year change of +10.4% [4] - The consensus for 'Revenue- Pump' is estimated at $134.50 million, showing an increase of +8.3% from the prior-year quarter [4] - 'Sales- Pump- United States' is expected to be $108.34 million, reflecting a year-over-year change of +10.1% [4] Geographic Sales Projections - 'Sales- Pump- Outside the United States' is estimated to be $26.16 million, indicating a +1.5% change from the year-ago quarter [5] - 'Sales- Supplies and Other- United States' is forecasted to reach $94.74 million, with a year-over-year change of +10.3% [5] - The estimated 'Geographic Sales- United States' stands at $203.09 million, reflecting a year-over-year change of -5.4% [5] International Sales Estimates - 'Sales- Supplies and Other- Outside the United States' is projected at $46.80 million, indicating a +10.6% change from the prior-year quarter [6] - The consensus for 'Geographic Sales- Outside the United States' is $72.94 million, showing a significant decline of -99.9% from the year-ago quarter [6] Pump Shipments Forecast - Total worldwide 'Pump Shipments' are expected to reach 35,032, compared to 34,000 in the same quarter last year [7] - 'Pump Shipments- Outside the United States' is projected at 9,400, down from 10,000 in the previous year [7] - 'Pump Shipments- United States' is estimated at 25,632, compared to 24,000 in the year-ago period [7] Stock Performance - Over the past month, shares of Tandem Diabetes Care have returned -6%, while the Zacks S&P 500 composite has changed by -1.4% [8] - TNDM currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]

Group 1: Market Overview - US stocks experienced volatility with the Nasdaq Composite falling 0.1% and the S&P 500 also shedding approximately 0.1%, while the Dow Jones Industrial Average remained stable above the flatline [1] - Concerns regarding AI's impact on various industries have led to a decline in the Dow and S&P 500, which have fallen in four of the past five weeks [2] Group 2: Earnings Reports - The final stretch of earnings season is underway, with Constellation Energy's results being closely watched for insights on AI's influence on energy demand, alongside reports from Medtronic and Palo Alto Networks [3] - Walmart's quarterly report, the first since reaching a trillion-dollar market cap, is anticipated as a highlight of the week [3] Group 3: Corporate Developments - Paramount Skydance's stock rose over 5% following news that Warner Bros. Discovery has requested a better offer from the studio after rejecting its latest bid [4] Group 4: Economic Indicators - A series of economic readings, including the delayed December Personal Consumption Expenditures index, are expected to be released, particularly after a cooler-than-expected consumer inflation report [5] - An advance look at fourth quarter GDP is scheduled for release, which will provide insights into economic health amid discussions on interest-rate cuts [6]

Earnings Reports Overview - The fourth-quarter earnings season is nearing its end, with several significant reports from retail, energy, and tech companies expected this week [1] - Key companies reporting include Palo Alto Networks, Carvana, Walmart, and Opendoor Technologies [1][2][4][7] Company-Specific Insights - **Palo Alto Networks**: Expected to report earnings of 94 cents per share on revenue of $2.58 billion [1] - **Carvana**: Anticipated to report quarterly earnings of $1.10 per share on revenue of $5.26 billion, despite concerns over a short-seller report alleging accounting irregularities [3] - **Walmart**: Projected to report earnings of 72 cents per share on revenue of $190.24 billion, with a focus on high-margin segments like advertising and e-commerce [4] - **Opendoor Technologies**: Investors are looking for updates on turnaround plans and progress toward 2026 profitability, particularly regarding gross margins and the AI-driven "capital-light" platform [7]

Financial Data and Key Metrics Changes - The company reported revenue of $9 billion, reflecting an 8.7% increase year-over-year and a 6% organic growth, which is a 50 basis point acceleration from the previous quarter [18][19] - Adjusted gross margin was 64.9%, ahead of expectations, with a 30 basis point benefit from pricing [19][20] - Adjusted operating profit was $2.2 billion, resulting in an adjusted operating margin of 24.1%, also ahead of expectations [21] Business Line Data and Key Metrics Changes - The cardiovascular portfolio delivered 11% year-over-year revenue growth, with 13% growth in the U.S., marking the strongest growth in the last 10 years, excluding COVID comparisons [12] - Cardiac rhythm management (CRM) contributed 15% of total revenue and grew 5%, driven by double-digit growth in Micra and over 70% growth in Aurora EV-ICD [12][13] - The neuroscience portfolio grew 3%, with expectations for the pipeline to impact growth in the fourth quarter [14][15] Market Data and Key Metrics Changes - U.S. growth was 6% year-over-year, the strongest performance since fiscal year 2019, excluding COVID comparisons [19] - In China, low single-digit growth was reported while navigating volume-based procurement challenges [19] - Western Europe experienced high single-digit growth, contributing to balanced geographical performance [19] Company Strategy and Development Direction - The company is focused on expanding its innovation pipeline, particularly in high-growth areas such as hypertension treatment with Symplicity and urinary incontinence with Altaviva [2][3] - The launch of the Hugo robotic system is seen as a significant growth driver, with initial installations and positive feedback from early cases [5][6] - The company is committed to M&A strategies, focusing on tuck-in deals that align with existing business segments [59][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue and earnings growth, highlighting strong contributors like CAS and CRM [10][24] - The company anticipates continued growth from new product launches and market expansions, particularly in the U.S. [10][39] - There is an expectation for high single-digit EPS growth in fiscal year 2027, despite some headwinds from tariffs and M&A activities [24][68] Other Important Information - The planned separation of the MiniMed diabetes business is on track, with expectations for completion by the end of calendar year 2026 [18] - The company is investing in R&D and marketing to support growth areas, particularly in renal denervation and Altaviva [66] Q&A Session Summary Question: Comments on accelerating revenue growth next year and high single-digit earnings growth - Management indicated that growth will continue, driven by strong performance in CAS and other growth drivers like Symplicity and Altaviva [30][39] Question: Monitoring progress for RDN and Altaviva - Management mentioned strong leading indicators, including training of over 500 physicians and opening of new accounts for RDN [43] Question: Thoughts on capital allocation and M&A strategy - The company is focused on tuck-in M&A opportunities that align with existing business segments, prioritizing high-growth areas [59][60] Question: Impact of Hugo on surgical business growth - Management expressed excitement about the Hugo system's potential, noting positive feedback from initial cases and strong leading indicators [87]

Medtronic (NYSE:MDT) Q3 2026 Earnings call February 17, 2026 08:00 AM ET Company ParticipantsGeoff Martha - Chairman and CEOIngrid Goldberg - VP and Head of Investor RelationsThierry Piéton - EVP and CFOConference Call ParticipantsChris Pasquale - Equity Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDanielle Antalffy - Equity Research Analyst of Medical Devices and SuppliesJoanne Wuensch - Managing Director and Senior Equity Research Analyst of Medical Technology ...

Financial Data and Key Metrics Changes - The company reported revenue of $9 billion, growing 8.7% reported and 6% organic, which is a 50 basis point acceleration from the prior quarter and 50 basis points above guidance [15][18] - Adjusted gross margin was 64.9%, ahead of expectations, with a 30 basis point benefit from pricing and a negative 100 basis points impact from mix [16][17] - Adjusted operating profit was $2.2 billion, resulting in an adjusted operating margin of 24.1%, also ahead of expectations [18] Business Line Data and Key Metrics Changes - The cardiovascular portfolio delivered 11% year-over-year revenue growth, with CAS growing 80% year-over-year, primarily driven by PFA [10][11] - Cardiac rhythm management (CRM) contributed 15% of total revenue and grew 5%, driven by double-digit growth in Micro and over 70% growth in Aurora EV-ICD [10] - Neuroscience portfolio grew 3%, with cranial and spinal technologies delivering mid-single-digit growth [11][12] - The diabetes business, MiniMed, delivered 15% reported and over 8% organic growth, led by strong performance in international markets [14] Market Data and Key Metrics Changes - U.S. growth was 6% year-over-year, the strongest performance since fiscal year 2019, excluding COVID comparisons [16] - In China, low single-digit growth was reported, with mid-single-digit growth excluding volume-based procurement impacts [16] Company Strategy and Development Direction - The company is focused on driving sustained innovation across its portfolio, with significant investments in R&D and M&A to capitalize on high-growth opportunities [5][22] - The launch of Hugo and the expansion of Symplicity and UltraViva are key growth drivers, with expectations for these products to significantly impact revenue in the coming quarters [8][9] - The company is committed to a two-step IPO and split for the MiniMed business, expected to be completed by the end of calendar year 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, highlighting strong contributors and businesses positioned for meaningful growth [8][22] - The company anticipates continued growth in the cardiovascular market, with expectations for high teens growth in fiscal 2027 [50] - Management acknowledged challenges in certain segments but emphasized plans to strengthen competitiveness and improve growth trajectories [9][22] Other Important Information - The company is actively pursuing M&A opportunities, focusing on tuck-in deals that align with its strategic goals [59] - The impact of tariffs on gross margin is expected to be approximately $185 million, with ongoing efforts to mitigate these effects [19][21] Q&A Session Summary Question: Comments on accelerating revenue growth next year - Management highlighted strong growth in CAS and other key drivers like Symplicity and UltraViva, expecting continued growth into FY 2027 [26][28] Question: Clarification on product launch progress for RDN and UltraViva - Management noted strong leading indicators for both products, including physician training and account openings, with plans to provide more concrete goalposts in the future [41][42] Question: Thoughts on capital allocation and M&A strategy - Management confirmed a focus on tuck-in M&A opportunities and strategic investments in high-growth areas, emphasizing a balanced approach to capital allocation [58][59] Question: Insights on CAS growth and market dynamics - Management expressed confidence in sustaining CAS growth, anticipating continued strong performance in the cardiovascular market [50][52] Question: Guidance for fiscal 2027 and EPS growth - Management reiterated high single-digit EPS growth guidance for FY 2027, factoring in various headwinds and growth drivers [66][69]

As filed with the Securities and Exchange Commission on February 17, 2026. Registration No. 333-293179 PROFUSA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Name, address, including zip code, and telephone number, including area code, of agent for service) Delaware 3841 86-343 ...

Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel® Radionuclide Therapy™ (PRnT™) is preparing to open two new production facilities. Previous corporate filings have included risk factors regarding the Company’s continued use of a single production site. For the past two years, the Company has been assessing alternate facilities. The Company’s strategic target is to have one domestic production facility, in which the Company ...

Core Viewpoint - Danaher is set to acquire Masimo, a pulse oximeter manufacturer, for $9.9 billion, aiming to enhance its diagnostics portfolio [1] Company Summary - The acquisition reflects Danaher's strategy to expand its capabilities in the diagnostics sector [1] - Masimo specializes in non-invasive monitoring technologies, particularly pulse oximetry, which is critical for patient care [1] Industry Summary - The deal signifies a trend in the healthcare industry where companies are consolidating to strengthen their product offerings in diagnostics [1] - The acquisition is expected to position Danaher more competitively in the growing market for medical devices and monitoring solutions [1]